Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes and Cardiovascular Disease: A Review
Diabetes Obes Metab 11(10):953965 Madsen K, Knudsen LB, Agersoe H, Nielsen PF, Thgersen H, Wilken M, Johansen NL (2007) Structure-activity and protraction relationship of long-acting glucagon- like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness
However, patches present their own adherence challenges, including skin irritation, adhesion problems, and the need for regular application site rotation
References: Buckley ST et al (2018): Transcellular stomach absorption of a derivative glucagon-like peptide-1 receptor agonist
As the interest in medications that help promote weight management and lower blood sugar for diabetics rises, GLP-1 has entered into the collective social awareness
Protease inhibitors can be co-administered to prevent enzymatic degradation